Brain Cancer Clinical Trials

Showing 141-160 of 693 trials

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

NCT05168423

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. In the dose expansion phase, the maximum tolerated dose (MTD) of CART-EGFR-IL13Ra2 cells will be determined using a standard 3+3 design. Once the MTD has been determined, the dose exploration phase will allow for further identification of a recommended dose for expansion (RDE) as well as the safety and feasibility of alternative dosing schedules.

Glioblastoma

University of Pennsylvania67 participantsStarted Feb 2023

Philadelphia, Pennsylvania, United States

NOT_YET_RECRUITINGPHASE2

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

NCT06804655

Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.

Brain (Nervous System) CancersGlioblastomaGlioma+5 more

University of Zurich40 participantsStarted Feb 2026

Basel, Basel-Landschaft, Switzerland • Sankt Gallen, Canton of St. Gallen, Switzerland • Zurich, Canton of Zurich, Switzerland

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Related Searches

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Multimodal Machine Learning Characterization of Solid Tumors

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma

Assessing Brain Metabolism Using MRS With Deuterated Glucose

MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Protoporphyrin Imaging in Multispectral Evaluation of Resections

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

Intraoperative Functional Ultrasound

Quality Improvement and Practice Based Research in Neurology Using the EMR

Phase 2 Clinical Trial of KH617

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas